Article Data

  • Views 468
  • Dowloads 150

Original Research

Open Access

Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1,550 patients

  • Y. Sun1
  • H. Meng2
  • Y. Jin1
  • X. Shi1
  • Y. Wu1
  • D. Fan3
  • X. Wang1
  • X. Jia4
  • H. Dai1,*,

1Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

2Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

3Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC, USA

4Department of Gynecology, Nanjing Maternity and Child Health Hospital, Affiliated Hospital of Nanjing Medical University, Nanjing, China

DOI: 10.12892/ejgo2854.2016 Vol.37,Issue 3,June 2016 pp.348-352

Published: 10 June 2016

*Corresponding Author(s): H. Dai E-mail: 15996312979@163.com

Abstract

Background: The study was performed to characterize and compare the serum lipid profile in gynecologic cancers and benign diseases. Materials and Methods: A total of 1,550 age-matched females were included in this study: 760 patients with gynecologic cancers and 790 patients with benign diseases. Serum levels of triglycerides (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), total cholesterol (TC), and lipoprotein (a) were measured. Results: Compared to gynecologic benign disease group, gynecologic cancer group was associated with higher level of TG (p = 0.0002), as well as lower level of HDL-c (p < 0.0001), LDL-c (p = 0.004) and TC (p = 0.003). Compared to benign ovarian tumor group, ovarian cancer group had significantly lower levels of HDL-c (p < 0.0001), LDL-c (p = 0.0009), and TC (p < 0.0001), as well as a trend of higher level of lipoprotein (a) (p = 0.10). Compared to endometriosis group, endometrial cancer group showed higher levels of TG (p < 0.0001) and lower levels of HDL-c (p = 0.002). There was no significant difference in any lipid parameters between cervical cancer group and uterine leiomyomas group. Conclusion: In conclusion, compared with benign diseases, gynecologic cancers are associated with a disordered lipid profile characterized by higher TG and lipoprotein (a) levels, and lower HDL-c, LDL-c, and TC levels. The association is most conspicuous in ovarian cancers. Endometrial cancer is accompanied by alterations only in TG and HDL-c levels, while cervical cancer does not appear to be associated with disordered lipid profile.

Keywords

Serum lipid; Ovarian cancer; Endometrial cancer; Cervical cancer.

Cite and Share

Y. Sun,H. Meng,Y. Jin,X. Shi,Y. Wu,D. Fan,X. Wang,X. Jia,H. Dai. Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1,550 patients. European Journal of Gynaecological Oncology. 2016. 37(3);348-352.

References

[1] Silvente-Poirot S., Poirot M.: “Cholesterol metabolism and cancer: the good, the bad and the ugly”. Curr. Opin. Pharmacol., 2012, 6, 673.

[2] Qadir M.I., Malik S.A.: “Plasma lipid profile in gynecologic cancers”. Eur. J. Gynaecol. Oncol., 2008, 2, 158.

[3] Melvin J.C., Holmberg L., Rohrmann S., Loda M., Van Hemelrijck M.: “Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses”. J. Cancer Epidemiol., 2013, 2013, 823.

[4] Danilo C., Frank P.G.: “Cholesterol and breast cancer development”. Curr. Opin. Pharmacol., 2012, 6, 677.

[5] Murtola T.J., Syvala H., Pennanen P., Bläuer M., Solakivi T., Ylikomi T., Tammela T.L.: “The importance of LDL and cholesterol metabolism for prostate epithelial cell growth”. PLoS One, 2012, 7, e39445.

[6] Guo E., Chen L., Xie Q., Chen J., Tang Z., Wu Y.: “Serum HDL-C as a potential biomarker for nodal stages in gastric cancer”. Ann. Surg. Oncol., 2007, 14, 2528.

[7] Jacobs R.J., Voorneveld P.W., Kodach L.L., Hardwick J.C.: “Cholesterol metabolism and colorectal cancers”. Curr. Opin. Pharmacol., 2012, 6, 690.

[8] Drabkin H.A., Gemmill R.M.: “Cholesterol and the development of clear-cell renal carcinoma”. Curr. Opin. Pharmacol., 2012, 6, 742.

[9] Borena W, Strohmaler S, Lukanova A, Bjørge T., Lindkvist B., Hallmans G., et al.: “Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults”. Int. J. Cancer, 2012, 131, 193.

[10] Yang HH, Chen XF, Hu W, Lv D.Q., Ding W.J., Tang L.J.,et al: “Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer”. Clin. Chem. Lab. Med., 2009, 47, 452.

[11] Cust A.E., Kaaks R., Friedenreich C., Bonnet F., Laville M., Tjønneland A., et al.: “Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)”. Endocr. Relat. Cancer, 2007, 14, 755.

[12] Liang S.J., Liou T.H., Lin H.W., Hsu C.S., Tzeng C.R., Hsu M.I.: “Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome”. Acta Obstet. Gynecol. Scand., 2012, 91, 1167.

[13] Al-Omari W.R., Nassir U.N., Sulaiman W.R.: “Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist”. Int. J. Gynaecol. Obstet., 1999, 66, 191.

[14] Bjorge T., Lukanova A., Tretli S., Manjer J., Ulmer H., Stocks T., et al.: “Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project”. Int. J. Epidemiol., 2011, 40, 1667.

[15] Ulmer H., Bjorge T., Concin H., Lukanova A., Manjer J., Hallmans G., et al.: “Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can)”. Gynecol. Oncol., 2012, 125, 330.

[16] Friedenreich C.M., Biel R.K., Lau D.C., Csizmadi I., Courneya K.S., Magliocco A.M., et al.: “Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer”. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 2384.

[17] Zhang Y., Liu Z., Yu X., Zhang X., Lü S., Chen X., Lü B.: “The association between metabolic abnormality and endometrial cancer: a large case-control study in China”. Gynecol. Oncol., 2010, 117, 41.

[18] Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults: “Chinese guidelines on prevention and treatment of dyslipidemia in adults”. Zhonghua Xin Xue Guan Bing Za Zhi, 2007, 35, 390.

[19] Uccello M, Malaguarnera, Pelligra E, Biondi A., Basile F., Motta M.: “Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma”. Indian J. Med. Paed. Oncol., 2011, 32, 71.

[20] Ahn J., Lim U., Weinstein S., Schatzkin A., Hayes R.B., Virtamo J., Albanes D.: “Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 2814.

[21] Fiorenza A., Branchi A., Sommariva D.: “Serum lipoprotein profile in patients with cancer: a comparison with non-cancer subjects”. Int. J. Clin. Res., 2000, 30, 141.

[22] Jacobs E., Gapstur S.: “Cholesterol and cancer: awareness and new questions”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 2805.

[23] Lindemann K., Vatten L.J., Ellstrom-Engh M., Eskild A.: “Serum lipids and endometrial cancer risk: results from the HUNT-II study”. Int. J. Cancer, 2009, 124, 2938.

[24] Borena W, Stocks T, Jonsson H, Strohmaier S., Nagel G., Bjørge T., et al.: “Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study”. Cancer Causes Control, 2011, 22, 291.

[25] Gadomska H., Janecki J., Marianowski L., Nowicka G.: “Lipids in serum of patients with malignant ovarian neoplasms”. Int. J. Gynaecol. Obstet., 1997, 57, 287.

[26] Ansell B., Watson K., Fogelman A., Navab M., Fonarow G.: “Highdensity lipoprotein function: recent advances”. JACC, 2005, 46, 1792.

[27] Kei A., Filippatos T.D., Tsimihodimos V., Elisaf M.S.: “A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease”. Metabolism, 2012, 61, 906.

[28] Kotani K., Tsuzaki K., Taniguchi N., Sakane N.: “LDL particle size and reactive oxygen metabolites in dyslipidemic patients”. Int. J. Prev. Med., 2013, 3, 160.

[29] Li A.J., Elmore R.G., Chen I.Y., Karlan B.Y.: “Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers”. Gynecol. Oncol., 2010, 116, 78.

[30] Jafri H., Alsheikh-Ali A., Karas R.: “Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy”. JACC, 2010, 55, 2846.

[31] Lippi G., Franchini M., Salvagno G.L., Guidi G.C.: “Lipoprotein(a) and cancer: anti-neoplastic effect besides its cardiovascular potency”. Cancer Treat. Rev., 2007, 33, 427.

[32] Siegel R., Naishadham D., Jemal A.: “Cancer statistics- 2012”. CA Cancer J. Clin., 2012, 62, 10.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top